Main Content

Search loading...

MOSAIQ takes top rank in KLAS Oncology 2014 report

For the second year in a row, the independent research firm, KLAS, announced that MOSAIQ® Oncology Information System earned the number one ranking in the medical and/or radiation oncology category of KLAS’s “Oncology 2014: Integration is Key” report. The survey of 247 customers of various vendors said that “Elekta has improved their MOSAIQ interfaces to take a commanding lead over their competitors.” MOSAIQ scored 82.4 out of 100, 93 percent of customers said they would buy again and 96 percent confirmed that MOSAIQ is part of their long-term plans.

In the “interface race,” in which integration is a top consideration among customers, providers were more pleased with Elekta’s MOSAIQ pharmacy interfaces than they were in the 2013 KLAS oncology report, achieving a rating of 8.0, eclipsing last year’s mark of 7.1. “Elekta’s single database for radiation and medical oncology continues to be a strength for the continuity of oncology care,” the report stated.

In the report, MOSAIQ was the highest performer in five out of eight categories, covering both medical and radiation oncology.

Why is this important to our customers?

MOSAIQ is at the heart of Elekta’s software vision: information-guided cancer care. This concept puts patients at the center, guiding the cancer management process. The entire care team is always informed and automated decision support tools, combined with clinical intelligence enable the care team to quickly adapt the patient’s treatment as needed. KLAS research is based on extensive surveys of many healthcare providers. It directly represents the provider voice and acts as a catalyst for improving supplier performance.

Fourth consecutive year: Leksell Gamma Knife® Perfexion™ earns first place in KLAS report

Leksell Gamma Knife® Perfexion™, Elekta’s premier intracranial radiosurgery system, took the top rank for the fourth year in a row in KLAS research firm’s 2014 Best in KLAS Awards: Medical & Infrastructure report1. In the report, Perfexion scored 94.5 out of 100 on the system’s functionality and upgrade capacity. Perfexion also scored between 90.5 and 93.5 on four other performance categories, including service and support, and implementation and training.

Further documenting the superior dosimetric performance of Perfexion, the results of two recent studies2-3 confirm the gentleness and effectiveness of Gamma Knife radiosurgery for patients with multiple metastases. Drs Lijun Ma and Masaaki Yamamoto presented their respective findings at the 17th International Leksell Gamma Knife Society Meeting, which convened May 11-15 in New York City.

1. 2014 Best in KLAS Award: Medical Equipment & Infrastructure, July 2014. © 2014 KLAS Enterprises, LLC All rights reserved.

2. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. The Lancet Oncol 2014:15:387-395

3. Ma L, Petti P, Wang B, et al. (2011) Apparatus dependence of normal brain tissue dose in stereotactic radiosurgery for multiple brain metastases. J Neurosurg 114(6):1580-1584. doi:10.3171/2011.1.JNS101056

Why is this important to our customers?

Gamma Knife technology has benefited patients for decades, amassing over 700,000 patient treatments at a current rate of over 70,000 patient treatments each year. Leksell Gamma Knife Perfexion, the latest generation of this constantly evolving intracranial radiosurgery platform, represents the future of stereotactic radiosurgery.

Elekta recognized by CDP for environmental commitment

The Carbon Disclosure Project (CDP) recognized Elekta for its actions to reduce carbon emissions and mitigate the business risks of climate change. Elekta has therefore been awarded a position on The A List: The CDP Climate Performance Leadership Index 2014. The index presents 187 listed companies identified as demonstrating a superior approach to climate change mitigation. It has been produced at the request of 767 investors who represent more than a third of the world’s invested capital by CDP, the international NGO that drives sustainable economies.

Elekta was also recently added to the FTSE4Good Index Series. This is a set of indices defined by the FTSE that measures the performance of companies demonstrating strong environmental, social and governance (ESG) practices.

Why is this important to our customers?

According to CDP, global greenhouse gas emissions continue to rise, threatening financial risk if not mitigated. A-List companies, such as Elekta, are responding to market demand for environmental accountability and at the same time are making progress towards the realization of sustainable economies.

Elekta leads market average in several categories, according to latest MD Buyline report

As in many previous quarterly reports, MD Buyline's Q1 2014 report ranks Elekta highly for key technologies in radiation therapy. Elekta leads the market average in 2-year trend ratings (Q2 2012-Q1 2014) in the categories of oncology information management systems, stereotactic radiosurgery (SRS) systems, remote afterloaders and treatment planning systems (TPS). Vendors are rated on a 1 to 10 scale according to user satisfaction with system performance, system reliability, system installation/implementation, applications training, service response time and service repair quality. MD Buyline clinical and IT analysts conduct interviews with hands-on users, including clinicians, physicians, biomedical engineers, physicists, nurses, CIOs and IT managers. Elekta’s ratings: OIS (9.1 v. Varian at 8.5), SRS (8.9), remote afterloader (8.9), TPS (9.0 v. Varian and Philips at 8.9)

Why is this important to our customers?

MD Buyline has provided healthcare facilities with business intelligence for over 25 years. MD Buyline’s highly respected recommendations on linear accelerators, stereotactic radiosurgery, oncology information systems and treatment planning systems technologies are used by clinicians and senior management to investigate and validate purchasing decisions.

2013 Medtech report puts Elekta in top 5 of 65 companies

Queen's Award

In the 2013 Medtech Value Creators Report, Elekta ranks fifth in a field of 65 medical-equipment manufacturers with a market valuation greater than $1 billion. The report was generated by The Boston Consulting Group, a global management consulting firm and the world’s leading advisor on business strategy. Rankings of medical-equipment manufacturers, in addition to medical-device companies, medical-supply companies and in vitro diagnostics companies – collectively the "medtech" sector – were based on the total shareholder return (TSR) percentage.

Why is this important to our customers?

According to the report, for more than 10 years, the medtech sector has outperformed the overall capital market in terms of financial performance. It has generated a TSR of 279 percent since 2001, substantially beating the MSCI World Index, which returned 98 percent over the same period.

"This key ranking among medical-equipment providers should send the message that Elekta is a vibrant, world-class company that creates value for shareholders and customers alike," says Elekta President and CEO, Tomas Pussepp.

Leksell Gamma Knife® Perfexion™ Named Best in KLAS for Radiation Therapy


In June 2013, Leksell Gamma Knife® Perfexion™ earned the number one ranking for radiation therapy in the KLAS research firm’s recently released 2013 Best in KLAS Awards: Medical Equipment & Infrastructure report. This is the second consecutive year in which Perfexion has won the Best in KLAS award for radiation therapy.

Why is this important to our customers?

This was an independent report from healthcare executives and professionals carried out by KLAS, which gathered performance rating over the past 12 months for medical equipment and infrastructure vendors. In the report, Perfexion scored 92.9 out of 100, and 96 percent of customers indicated they would buy again. On a 1 to 9 scale, Perfexion received an 8.7 from respondents for satisfaction with product uptime, the highest score among all vendors rated in the market segment.

Elekta Wins IOP Innovation Award for Development of Agility MLC

The Institute of Physics (IOP) recently named Elekta as one of the companies chosen to receive an IOP Innovation Award for physics innovation in the UK and Ireland. One of five recipients, the company was selected based on the development of our Agility™ multileaf collimator. The innovative design of Agility, based on physics research and development, utilizes industry-leading technology to provide faster, more accurate, and more versatile radiation therapy for individuals with cancer.

Your Feedback:

Send message Close window